Fred M. Schwarzer , J.D. - Chairman
Managing Partner, Charter Life Sciences

Mr. Schwarzer joined the board in 2007 and was appointed Chairman in March of 2009. Prior to founding Charter Life Sciences, Mr. Schwarzer was the chief executive officer and then chairman of Heska (HSKA), where he completed major corporate partnership and acquisitions and Heska’s initial public offering and follow-on public offering. Mr. Schwarzer served as president and CEO of Mingly Capital Corporation, which focused on developing cross-border opportunities in life sciences and information technology. He was a senior vice president of C.M. Capital, a diversified asset management company. Mr. Schwarzer founded General Counsel Associates, and was a partner with Pillsbury, Madison & Sutro. Mr. Schwarzer received a J.D. from the University of California, Berkeley, Boalt Hall School of Law and a B.A. from the University of Michigan.
top of page

Gregory Johnson, Ph.D.
Managing Director, Prolog Ventures
 
Dr. Johnson joined Kereos as a Director in September of 2005 bringing with him over two decades of venture capital experience.  Prior to joining Prolog, he was Vice President of Monsanto Venture Capital and Monsanto’s director of new ventures and technology where he oversaw Monsanto’s $80 million portfolio of corporate venture investments.  Dr. Johnson also spent 14 years as a general partner at Gateway Associates, a St. Louis-based venture capital company with more than $180 million in total funds under management.  Besides Kereos, he also sits on the Boards of Everest, Singulex, and Stereotaxis.  Dr Johnson holds a doctoral degree in physics from the University of Rochester and a bachelor’s degree from MIT.
top of page

Michael D. Loberg, Ph.D.
Independent
 
Dr. Loberg joined Kereos as a board member in January 2004. He recently served as President and CEO of NitroMed, and also on the board of Advanced Magnetics. In 2003 Dr. Loberg oversaw and led NitroMed’s initial public offering process. Previously, Dr. Loberg spent nearly 20 years with the Bristol-Myers Squibb (BMS) organization, most recently as President, BMS Oncology & Immunology. He also served as President, BMS Primary Care division; President, BMS Northern Europe; President, BMS Specialty Pharmaceuticals; President, Squibb Diagnostics; and Vice President for Diagnostic R&D, E.R. Squibb & Sons. Prior to BMS, Dr. Loberg served as Associate Professor in the University of Maryland Schools of Pharmacy and Medicine. He holds a Ph.D. in Chemistry from Washington University.
top of page

John Rice, Ph.D.
Managing Partner, Triathlon Medical Ventures

Dr. Rice was appointed as a Kereos director in September 2005. Previous to joining Triathlon Medical Ventures, he was a Managing Director at Senmed Medical Ventures and served as a member of the investment committee. In addition to his investment experience, Dr. Rice spent 13 years with Battelle Memorial Institute in various capacities, including overseeing Battelle's international biotechnology activities. Other boards he serves on include Bio/Start and Omeris. Dr. Rice earned a BS in Microbiology, as well as M.S. and Ph.D. degrees in Microbiology and Virology from The Ohio State University.
top of page

Stephen Snowdy, Ph.D.
MB Venture Partners

Dr. Snowdy joined the board in 2005. He brings to the team extensive academic training in life sciences and finance, having been the first person to earn simultaneous PhD and MBA degrees at the University of North Carolina, Chapel Hill. Dr Snowdy's PhD, which is in Neurobiology, was focused on studying the mechanisms by which viruses make their way through the cells that they infect. His MBA was heavily focused in finance. Dr. Snowdy obtained a bachelor's degree in Chemistry from the University of Florida, where he also completed two years of post-baccalaureate study in cardio pharmacology. His PhD, undergraduate and post-baccalaureate studies culminated in several academic publications. Dr. Snowdy's academic training followed service in the United States Navy where he was a Navy Diver assigned to nuclear submarines.
top of page

Samuel A. Wickline, M.D.
Professor of Medicine, Physics and Biomedical Engineering, Washington University
Co-Director of Cardiovascular Division, Washington University School of Medicine
 
Dr. Wickline is a founder of Kereos and Chair of the Scientific Advisory Board, and has served as a board member since inception. He is Co-Director of the Cardiovascular Division of the Washington University School of Medicine (WUSM) and Professor of Medicine, Physics, Biomedical Engineering, and Cell Biology at WU. Dr. Wickline’s investigative work has focused on molecular imaging and targeted therapy of cardiovascular disease, as well the use of magnetic resonance and ultrasonic tissue characterization of heart and vascular tissues, and he is the author of over 150 publications in these and related fields. He holds an M.D. degree from the University of Hawaii.
top of page